Glaxosmithkline Pharmaceuticals Ltd. (GLAXO): Glaxosmithkline Pharmaceuticals Share Price Rises 2.34% Today
- September 16, 2026
- Posted by: Harsh Piplani
- Category: News
Glaxosmithkline Pharmaceuticals Ltd. share price rose today, with GLAXO Share Price at Rs 2,880, up 2.34% from the previous close of Rs 2,814.1. The company’s market capitalisation stands at Rs 48,063.88 crore, placing the move in a sizeable listed healthcare name. The session’s price rise is clearly verified by the data, but the supplied figures do not establish a company-specific catalyst.
For readers tracking GLAXO Share Price Today, the move is notable because it came after an opening level of Rs 2,807, a low of Rs 2,758.35 and a high that matched the closing price at Rs 2,880. Turnover stood at Rs 1.41 crore, which is a factual traded-value measure and should be read alongside the day’s price action rather than as a signal by itself. In Univest’s stock news view, the event matters because the stock moved higher on a day when valuation, sector positioning and company fundamentals remain in focus.
From a market-news angle, GLAXO Stock News today is best understood as a verified share price rise, not as a claim-driven story. Univest notes that investors usually look next at the close relative to the day’s range, the company’s earnings quality and how the stock compares with healthcare peers on valuation and profitability. The available data gives enough context for a grounded stock analysis, even without a stated trigger.
GLAXO Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,880 |
| Previous Close | Rs 2,814.1 |
| Today's Move | Rs 65.9 (+2.34%) |
| Open | Rs 2,807 |
| High | Rs 2,880 |
| Low | Rs 2,758.35 |
| Turnover | Rs 1.41 crore |
| Market Capitalisation | Rs 48,063.88 crore |
| Market Cap Category | Large Cap |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) rose to Rs 2,880 from the previous close of Rs 2,814.1, a move of Rs 65.9 or 2.34%. The stock opened at Rs 2,807, reached a high of Rs 2,880, recorded a low of Rs 2,758.35.
GLAXO Share Price Today closed at Rs 2,880 after rising Rs 65.9, or 2.34%, versus the previous close of Rs 2,814.1. The stock opened at Rs 2,807, moved between Rs 2,758.35 and Rs 2,880, and finished at the day’s high. That sequence confirms a clear same-day price rise in a healthcare counter that remained active in the Indian Stock Market narrative today. The turnover of Rs 1.41 crore adds trading context, while the company’s market cap of Rs 48,063.88 crore keeps the move relevant within the broader Share Market Today discussion. For Univest readers, the key point is simple: the stock ended stronger than it began, and the supplied data confirms the size of the move without attaching an unverified reason.
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 48,063.88 crore |
| P/E Ratio | 44.63x |
| P/B Ratio | 18.92x |
| ROE | 48.76% |
| ROCE | 66.79% |
| EPS | Rs 63.05 |
| Book Value Per Share | Rs 148.77 |
| Dividend Yield | 2.03% |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) fundamental metrics show P/E 44.63x, P/B 18.92x, ROE 48.76%, ROCE 66.79%. These figures provide context only and are not a buy or sell signal.
Glaxosmithkline Pharmaceuticals Ltd. has a market capitalisation of Rs 48063.88 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 44.63x, P/B at 18.92x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 48.76% and ROCE of 66.79%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 63.05, book value per share of Rs 148.77, dividend yield of 2.03%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.74x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 44.63x |
| Benchmark Median P/E | 31.74x |
| Benchmark Average P/E | 47.98x |
| Benchmark P/E Range | 3.29x to 683.37x |
| Company P/B Ratio | 18.92x |
| Benchmark Median P/B | 3.02x |
| Company ROE | 48.76% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 66.79% |
| Benchmark Median ROCE | 13.65% |
| Company Market Capitalisation | Rs 48,063.88 crore |
| Benchmark Median Market Cap | Rs 750.5 crore |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a P/E ratio of 44.63x, which is above the benchmark median of 31.74x, a difference of +40.61%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a ROE of 48.76%, which is above the benchmark median of 11.78%, a difference of +313.92%. Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a ROCE of 66.79%, which is above the benchmark median of 13.65%, a difference of +389.3%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,41,957.5 | 36.4 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,47,576 | 83.41 | 13.81 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,89,233.01 | 84.58 | 20.55 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,11,670.55 | 24.29 | 4.07 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,10,272.68 | 32.62 | 3.13 | 11.83 | 16 |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a P/E ratio of 44.63x compared with the displayed peer median of 36.4x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 48.76% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 66.79% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a market capitalisation of Rs 48,063.88 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching GLAXO
- GLAXO Share Price rose 2.34% today to Rs 2,880, and the close matched the day’s high.
- The company’s market capitalisation stands at Rs 48,063.88 crore, giving the move meaningful listed-company context.
- P/E at 44.63 and P/B at 18.92 place the stock above several healthcare peers on valuation ratios.
- ROE of 48.76% and ROCE of 66.79% are the highest among the supplied peer set.
- Turnover of Rs 1.41 crore and the day’s range between Rs 2,758.35 and Rs 2,880 frame the session’s price action.
About Glaxosmithkline Pharmaceuticals Ltd.
Glaxosmithkline Pharmaceuticals Ltd. is part of the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is listed on the NSE and BSE under the symbol GLAXO. Based on the supplied data, the stock is tracked in the Indian pharmaceutical space alongside companies such as Sun Pharma, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. That makes GLAXO Stock News relevant not only for the day’s share price rise, but also for broader sector comparison.
The company’s financial profile in the supplied data suggests a business with strong earnings and capital-return ratios, with EPS at Rs 63.05, book value at Rs 148.77 and dividend yield at 2.03%. Those figures help frame the GLAXO Share Price beyond one trading session. Investors using Univest for company news and stock analysis can place the stock within healthcare fundamentals, valuation and peer context rather than looking at the day’s move in isolation.
Track GLAXO Share Price on Univest
Use Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Readers can track GLAXO Share Price on Univest for live share price updates, company news, fundamental ratios, shareholding pattern, market cap, 52-week levels and market insights. Univest also presents GLAXO share price today in a format that helps users connect the day’s move with valuation, sector performance and listed peer comparison.
For users following GLAXO Latest News, Univest is designed to keep the stock in one place with a clean stock-detail view, helping readers check the share price rise, review company financials and compare the name with other healthcare companies.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is GLAXO Share Price rising today?
Ans. GLAXO Share Price rose 2.34% today to Rs 2,880. The supplied data confirms the price event, but it does not establish a company-specific catalyst behind the move. The previous close was Rs 2,814.1.
What is the current GLAXO Share Price Today?
Ans. GLAXO Share Price Today is Rs 2,880. It is Rs 65.9 above the previous close of Rs 2,814.1, and the day’s move reflects a verified same-session gain. The previous close was Rs 2,814.1.
What is GLAXO’s market capitalisation?
Ans. GLAXO has a market capitalisation of Rs 48,063.88 crore. That places the company well above the industry median in the supplied benchmark and supports its standing in healthcare comparisons. The company operates in the Healthcare sector.
How do GLAXO’s valuation ratios look?
Ans. GLAXO trades at a P/E of 44.63 and a P/B of 18.92. Both ratios are above several supplied peers and sit above the industry median, which frames the valuation discussion.
What do GLAXO’s ROE and ROCE show?
Ans. GLAXO reports ROE of 48.76% and ROCE of 66.79%. These are strong absolute readings in the supplied data and exceed the benchmark medians for the same industry set. ROE stands at 48.76%.
How does GLAXO compare with healthcare peers?
Ans. GLAXO’s ROE and ROCE are higher than the supplied peer set, while its P/E sits between lower-multiple and higher-multiple pharma names. That creates a mixed but clearly defined peer position.
Should investors track GLAXO Share Price on Univest?
Ans. Yes. Univest lets readers track GLAXO Share Price, company news, market cap, valuation ratios, shareholding pattern and healthcare sector context in one place for a fuller stock analysis view. The previous close was Rs 2,814.1.
